|  |
| --- |
| **Outcome** | **N** |  | **Statin-dose combination** | **P** |
| **Simvastatin10-20 mg**116185 | **Simvastatin40-80 mg**41568 | **Atorvastatin10-20 mg**70359 | **Atorvastatin40-80 mg**3268 |
| HepatotoxicityAll grades | 231380 | N (%)Unadj. HRAdj. HR | 247 (0.21%)1 (ref)1 (ref) | 134 (0.32%)1.6 (1.3, 1.9), P<0.0011.3 (1.0, 1.6), P=0.025 | 196 (0.28%)1.2 (1.0, 1.5), P=0.031.3 (1.0, 1.5), P=0.02 | 30 (0.92%)4.4 (3.0, 6.4), P<0.0013.5 (2.4, 5.1), P<0.001 | <0.001<0.001 |
| HepatotoxicityModerate to severe | 231380 | N (%)Unadj. HRAdj. HR | 59 (0.05%)1 (ref)1 (ref) | 34 (0.08%)1.7 (1.1, 2.5), P=0.021.4 (0.9, 2.2), P=0.10 | 51 (0.07%)1.3 (0.9, 1.9), P=0.131.4 (1.0, 2.0), P=0.08 | 14 (0.43%)8.6 (4.8, 15.4), P<0.0018.0 (4.4, 14.6), P<0.001 | <0.001<0.001 |

**S2 Table:** Hazard ratio (HR) estimates (95% CI) for significant lab events associated with statin-dose combinations during the first 6 months therapy after recruitment, relative to low dose simvastatin. 9438 patients with MI within 30 days prior to recruitment were excluded.

N = number